Vertex Pharmaceuticals Incorporated
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRTX research report →
Companywww.vrtx.com
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.
- CEO
- Reshma Kewalramani
- IPO
- 1991
- Employees
- 6,100
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $109.25B
- P/E
- 25.21
- P/S
- 8.91
- P/B
- 5.65
- EV/EBITDA
- 20.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 86.28%
- Op Margin
- 38.97%
- Net Margin
- 35.40%
- ROE
- 23.93%
- ROIC
- 17.74%
Growth & Income
- Revenue
- $12.07B · 9.57%
- Net Income
- $3.95B · 838.09%
- EPS
- $15.46 · 843.27%
- Op Income
- $4.76B
- FCF YoY
- 504.13%
Performance & Tape
- 52W High
- $507.92
- 52W Low
- $362.50
- 50D MA
- $443.71
- 200D MA
- $434.42
- Beta
- 0.30
- Avg Volume
- 1.28M
Get TickerSpark's AI analysis on VRTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Bunnage Mark E. | sell | 33 |
| May 15, 26 | Bozic Carmen | sell | 1,354 |
| May 12, 26 | Bozic Carmen | sell | 6,988 |
| May 1, 26 | Upadhyay Suketu | other | 796 |
| May 1, 26 | Upadhyay Suketu | other | 2,866 |
| May 1, 26 | Upadhyay Suketu | sell | 796 |
| May 1, 26 | Thornberry Nancy | other | 472 |
| May 1, 26 | Thornberry Nancy | sell | 398 |
| May 1, 26 | Thornberry Nancy | other | 1,433 |
| May 1, 26 | Thornberry Nancy | other | 398 |
Our VRTX Coverage
We haven't published any research on VRTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VRTX Report →